Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice

Berton, 1999, Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain, Neuroscience, 92, 327, 10.1016/S0306-4522(98)00742-8 Bornstein, 1998, Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary–adrenal function, body weight, and metabolic regulation, Endocrinology, 139, 1546, 10.1210/en.139.4.1546 Chalmers, 1995, Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression, J. Neurosci., 15, 6340, 10.1523/JNEUROSCI.15-10-06340.1995 Chalmers, 1996, Corticotrophin-releasing factor receptors: from molecular biology to drug design, Trends Pharmacol. Sci., 17, 166, 10.1016/0165-6147(96)81594-X D'Aquila, 1994, Effects of chronic mild stress on performance in behavioural tests relevant to anxiety and depression, Physiol. Behav., 56, 861, 10.1016/0031-9384(94)90316-6 Deak, 1999, The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress, Endocrinology, 140, 79, 10.1210/en.140.1.79 Griebel, 2002, J. Pharmacol. Exp. Ther., 301, 333, 10.1124/jpet.301.1.333 Griebel, 2002, Anxiolytic and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders, Proc. Natl. Acad. Sci. U.S.A., 99, 6370, 10.1073/pnas.092012099 Heisler, 1997, Fluoxetine decreases fat and protein intakes but not carbohydrate intake in male rats, Pharmacol, Biochem. Behav., 58, 767, 10.1016/S0091-3057(97)00036-1 Heisler, 1999, Reduction of fat and protein intakes but not carbohydrate intake following acute and chronic fluoxetine in female rats, Pharmacol. Biochem. Behav., 63, 377, 10.1016/S0091-3057(99)00021-0 Holsboer, 1999, The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety, J. Psychiatr. Res., 33, 181, 10.1016/S0022-3956(98)90056-5 Holsboer, 1984, Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression, N. Engl. J. Med., 311, 1127, 10.1056/NEJM198410253111718 Kasckow, 2001, Corticotropin-releasing hormone in depression and post-traumatic stress disorder, Peptides, 22, 845, 10.1016/S0196-9781(01)00399-0 Keck, 2001, The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats, Eur. J. Neurosci., 13, 373, 10.1046/j.0953-816X.2000.01383.x Kopp, 1999, The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice, Behav. Pharmacol., 10, 73, 10.1097/00008877-199902000-00007 Mansbach, 1997, Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist, Eur. J. Pharmacol., 323, 21, 10.1016/S0014-2999(97)00025-3 Munoz, 1999, Alnespirone (S 20499), an agonist of 5-HT1A receptors, and imipramine have similar activity in a chronic mild stress model of depression, Pharmacol. Biochem. Behav., 63, 647, 10.1016/S0091-3057(99)00031-3 O'Brien, 2001, Are CRF receptor antagonists potential antidepressants?, Hum. Psychopharmacol., 16, 81, 10.1002/hup.187 Okuyama, 1999, Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001, J. Pharmacol. Exp. Ther., 289, 926 Papp, 2000, The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats, Behav. Brain Res., 115, 19, 10.1016/S0166-4328(00)00230-8 Sanchez, 2000, The selective sigma(2) ligand Lu 28–179 has an antidepressant-like profile in the rat chronic mild stress model of depression, Behav. Pharmacol., 11, 117, 10.1097/00008877-200004000-00003 Siegel, 1988 Vale, 1981, Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin, Science, 213, 1394, 10.1126/science.6267699 Vale, 1983, Chemical and biological characterization of corticotropin-releasing factor, Recent Prog. Horm. Res., 39, 245 Webster, 1996, In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation, Endocrinology, 137, 5747, 10.1210/en.137.12.5747 Willner, 1984, The validity of animal models of depression, Psychopharmacology, 83, 1, 10.1007/BF00427414 Willner, 2002, Animal models of depression: a diathesis/stress approach, vol. II, 703 Willner, 1987, Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant, Psychopharmacology, 93, 358, 10.1007/BF00187257 Willner, 1992, Chronic mild stress-induced anhedonia: a realistic animal model of depression, Neurosci. Biobehav. Rev., 16, 525, 10.1016/S0149-7634(05)80194-0 Yamano, 2000, Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice, J. Pharmacol. Exp. Ther., 292, 181 Zobel, 2000, Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated, J. Psychiatr. Res., 34, 171, 10.1016/S0022-3956(00)00016-9 Zorrilla, 2002, Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat, Brain Res., 952, 188, 10.1016/S0006-8993(02)03189-X